Replies to post #674 on Viking Therapeutics Inc (VKTX)

[Titan V]

That's what I thought as well. By the way, I'm curious if we will get any new info at AASLD on Oct 20-24.

Significant improvements were also observed in other NASH-related genes of interest, including CYP7A1 (cholesterol metabolism), MAP3K5 (ASK1, oxidative stress), ANXA2 (inflammation), KRT18 (CK-18, cell apoptosis), ACTA2 (aSMA, fibrosis) and LGALS1 (Galectin 1, fibrosis). Detailed results from this study will be presented at the 68th annual meeting of the American Association for the Study of Liver Diseases (AASLD), October 20-24, 2017 in Washington, D.C.

https://aasld2014.uberflip.com/i/842331-2017lmbrochure/9?m4=

http://www.prnewswire.com/news-releases/viking-therapeutics-announces-results-of-gene-expression-analysis-from-in-vivo-study-of-vk2809-in-non-alcoholic-steatohepatitis-nash-300516852.html